Levent Mutlu, MD
Instructor
Research & Publications
Biography
News
Coauthors
Selected Publications
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian CancerGelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.
- Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2.Santin A, McNamara B, Siegel E, Harold J, Mutlu L, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Dottino P, Schwartz P, Bellone S. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. Journal Of Clinical Oncology 2023, 41: 5599-5599. DOI: 10.1200/jco.2023.41.16_suppl.5599.
- Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA BiomarkersBellone S, McNamara B, Mutlu L, Demirkiran C, Hartwich T, Harold J, Yang-Hartwich Y, Siegel E, Santin A. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. International Journal Of Molecular Sciences 2023, 24: 8873. PMID: 37240216, PMCID: PMC10219151, DOI: 10.3390/ijms24108873.
- Abstract 3402: In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancerMcNamara B, Demirkiran C, Bellone S, Mutlu L, Zipponi M, Verzosa M, Harold J, Hartwich T, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Santin A. Abstract 3402: In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancer. Cancer Research 2023, 83: 3402-3402. DOI: 10.1158/1538-7445.am2023-3402.
- Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitorMcNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.
- Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”Harold J, Bellone S, Manavell D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”. Gynecologic Oncology 2023, 170: 334. PMID: 36906375, PMCID: PMC10266020, DOI: 10.1016/j.ygyno.2023.01.029.
- Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancerMcNamara B, Chang Y, Mutlu L, Harold J, Santin A. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. Expert Opinion On Biological Therapy 2023, 23: 227-233. PMID: 36800548, DOI: 10.1080/14712598.2023.2182679.
- The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivoHan C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.
- Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionMauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.
- Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitorManavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.
- EP007/#994 Bay 1895344, a novel ATR inhibitor, demonstrates in vivo activity against ATRX altered uterine leiomyosarcomaHarold J, Manavella D, Bellone S, Siegel E, Hartwich T, Zammataro L, Mutlu L, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. EP007/#994 Bay 1895344, a novel ATR inhibitor, demonstrates in vivo activity against ATRX altered uterine leiomyosarcoma. 2022, a51.1-a51. DOI: 10.1136/ijgc-2022-igcs.98.
- EP015/#546 In vitro and in vivo efficacy of trastuzumab deruxtecan (T-DXd) in epithelial ovarian cancer with HER2/NEU overexpressionMutlu L, Manavella D, Bellone S, Santin A. EP015/#546 In vitro and in vivo efficacy of trastuzumab deruxtecan (T-DXd) in epithelial ovarian cancer with HER2/NEU overexpression. 2022, a54.2-a54. DOI: 10.1136/ijgc-2022-igcs.106.
- Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaHarold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
- Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive OutcomesMutlu L, Manavella D, Gullo G, McNamara B, Santin A, Patrizio P. Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes. Cancers 2022, 14: 5187. PMID: 36358604, PMCID: PMC9656291, DOI: 10.3390/cancers14215187.
- BAY1895344, a novel ataxia telangiectasia and RAD3-related (ATR) inhibitor, is active in vivo against ATRX mutated uterine leiomyosarcoma (212)Harold J, Manavella D, Bellone S, Siegel E, Mauricio D, Hartwich T, Zammataro L, Mutlu L, AlAshqar A, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. BAY1895344, a novel ataxia telangiectasia and RAD3-related (ATR) inhibitor, is active in vivo against ATRX mutated uterine leiomyosarcoma (212). Gynecologic Oncology 2022, 166: s118. DOI: 10.1016/s0090-8258(22)01437-8.
- Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)Manavella D, Harold J, Bellone S, Hartwich T, Mutlu L, Tymon-Rosario J, Siegel E, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011). Gynecologic Oncology 2022, 166: s9. DOI: 10.1016/s0090-8258(22)01229-x.
- Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor (043)Tymon-Rosario J, Manara P, Manavella D, Bellone S, Siegel E, Hartwich T, Harold J, Zammataro L, Yang-Hartwich Y, Mutlu L, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor (043). Gynecologic Oncology 2022, 166: s30. DOI: 10.1016/s0090-8258(22)01262-8.
- In Vivo and In Vitro Efficacy of Enhertu in Uterine Serous Carcinoma (047)Mutlu L, Manavella D, Bellone S, Harold J, Mauricio D, Tymon-Rosario J, Siegel E, Hartwich T, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Enhertu in Uterine Serous Carcinoma (047). Gynecologic Oncology 2022, 166: s32-s33. DOI: 10.1016/s0090-8258(22)01266-5.
- Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sitesMutlu L, Li J, Tymon-Rosario J, Hui P, Menderes G. Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. Gynecologic Oncology 2021, 162: s113-s114. DOI: 10.1016/s0090-8258(21)00857-x.
- Robotic Lymph Node Resection Off the Aortic Bifurcation for Presumed Recurrence Management of Advanced Ovarian CancerMutlu L, Khadraoui W, Khader T, Menderes G. Robotic Lymph Node Resection Off the Aortic Bifurcation for Presumed Recurrence Management of Advanced Ovarian Cancer. Journal Of Minimally Invasive Gynecology 2020, 27: s97. DOI: 10.1016/j.jmig.2020.08.123.
- 83: Technique for retrograde robotic hysterectomy for management of dense bladder adhesionsGetaneh F, Mutlu L, Seifi F. 83: Technique for retrograde robotic hysterectomy for management of dense bladder adhesions. American Journal Of Obstetrics And Gynecology 2020, 222: s860. DOI: 10.1016/j.ajog.2019.12.232.
- Minimal Blood Loss in Robotic Assisted Laparoscopic Myomectomy: Bulldog Clamp for Temporary Ligation of Uterine Arteries and Uteroovarian VesselsSeifi F, Mutlu L, Tierney C, Azodi M. Minimal Blood Loss in Robotic Assisted Laparoscopic Myomectomy: Bulldog Clamp for Temporary Ligation of Uterine Arteries and Uteroovarian Vessels. Journal Of Minimally Invasive Gynecology 2019, 26: s66. DOI: 10.1016/j.jmig.2019.09.663.
- 2615 Robotic Tumor Debulking Off External Iliac Vessels for Management of Recurrent Ovarian CancerMutlu L, Khadraoui W, Hosier H, Menderes G. 2615 Robotic Tumor Debulking Off External Iliac Vessels for Management of Recurrent Ovarian Cancer. Journal Of Minimally Invasive Gynecology 2019, 26: s226-s227. DOI: 10.1016/j.jmig.2019.09.488.
- Robotic Interval Cytoreductive Surgery for Stage IV Epithelial Ovarian CancerMutlu L, Khadraoui W, Kim S, Menderes G. Robotic Interval Cytoreductive Surgery for Stage IV Epithelial Ovarian Cancer. Journal Of Minimally Invasive Gynecology 2019, 26: s17. DOI: 10.1016/j.jmig.2019.09.059.
- Robotic Colostomy Take-DownKim S, Mutlu L, Altwerger G, Menderes G. Robotic Colostomy Take-Down. Journal Of Minimally Invasive Gynecology 2019, 26: s16. DOI: 10.1016/j.jmig.2019.09.058.
- 1948 Robotic Type II B Posterior Exenteration for Recurrent Vaginal CancerKhadraoui W, Zeybek B, Mutlu L, Menderes G. 1948 Robotic Type II B Posterior Exenteration for Recurrent Vaginal Cancer. Journal Of Minimally Invasive Gynecology 2019, 26: s223. DOI: 10.1016/j.jmig.2019.09.479.
- Fertilization and ImplantationMutlu L, Taylor H. Fertilization and Implantation. 2017, 65-90. DOI: 10.1007/978-3-319-52210-4_4.
- Frequent migration of ectopic endometrial cells to the brain in a murine model of endometriosisSamani E, Li F, Krikun G, Ilagan Y, Mutlu L, Zhou Y, Naqvi H, Taylor H. Frequent migration of ectopic endometrial cells to the brain in a murine model of endometriosis. Fertility And Sterility 2015, 104: e69. DOI: 10.1016/j.fertnstert.2015.07.211.
- Geographical variability in outcome of donor egg IVF suggests ecological implications for ART success. a retrospective cohort analysis of 71, 182 donor egg IVF cyclesMoustafa S, Skrip L, Mutlu L, Pal L. Geographical variability in outcome of donor egg IVF suggests ecological implications for ART success. a retrospective cohort analysis of 71, 182 donor egg IVF cycles. Fertility And Sterility 2015, 104: e138. DOI: 10.1016/j.fertnstert.2015.07.427.
- Circulating endometriosis-derived mesenchymal stem cells in murine experimental endometriosisLi F, Samani E, Mutlu L, Taylor H. Circulating endometriosis-derived mesenchymal stem cells in murine experimental endometriosis. Fertility And Sterility 2015, 104: e69. DOI: 10.1016/j.fertnstert.2015.07.210.
- Fertilization and ImplantationMutlu L, Macer M, Taylor H. Fertilization and Implantation. 2013, 75-90. DOI: 10.1007/978-1-4614-6837-0_5.
- Identification of putative fallopian tube progenitor stem cellsSnegovskikh V, Massasa E, Mutlu L, Modi M, Taylor H. Identification of putative fallopian tube progenitor stem cells. Fertility And Sterility 2012, 98: s21. DOI: 10.1016/j.fertnstert.2012.07.076.